drugset / Trial / NCT00067028
Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy.
Timeline
- Start
- 2003-12
- Primary completion
- 2013-06
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 22.5 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 0.75 g | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | Intravenous |
| Subject | Idarubicin | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 10 mg/m2 | Intravenous |